Skip to main content

Table 4 Functional data for Placebo-control Group

From: Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy

  Baseline Post-placebo P value
LAFS 2-D1 (mean% ± SD) 33.51 ± 4.00 31.95 ± 4.2 0.31
Mitral TDI S’1 (mean m/s ± SD) 0.07810 ± 0.0149 0.0767 ± 0.0234 0.83
LVOT Vmax2 [median m/s (IQR)] 1.03 (0.89, 2.32) 1.94 (1.12, 1.99) 0.22
RVOT Vmax1 (mean m/s ± SD) 1.02 ± 0.19 1.29 ± 0.29 0.01
HR at LVOT Vmax1 (mean bpm ± SD) 201.7 ± 20.55 209.3 ± 23.44 0.48
HR at RVOT Vmax1 (mean bpm ± SD) 187.3 ± 10.86 201.7 ± 25.64 0.10
  1. 1Paired T test
  2. 2Wilcoxon matched-pairs signed rank test
  3. LAFS, left atrial fractional shortening; 2-D, 2-dimensional echocardiography; SD, standard deviation; LVFS, left ventricular fractional shortening; TDI, tissue Doppler imaging; LVOT Vmax, left ventricular outflow tract maximal velocity, IQR interquartile range, RVOT Vmax, right ventricular outflow tract maximal velocity
\